The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database
- 1 December 2016
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 102, 96-100
- https://doi.org/10.1016/j.lungcan.2016.11.003
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.Cancer and Metastasis Reviews, 2016
- Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?Journal of Thoracic Oncology, 2016
- Lung cancer at the intensive care unit: The era of targeted therapyLung Cancer, 2015
- Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized MedicineCurrent Drug Targets, 2015
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancerAnnals Of Oncology, 2014
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working groupLung Cancer, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009